Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus MAXAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus MAXAIR.
AEROLATE III vs MAXAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Category C
Category C
Bronchodilator
Bronchodilator